Skip to content
Announcement:

We are delighted to announce the release of a new scientific publication in collaboration with the University of Newcastle on modelling Stargardt disease (STGD1) in vitro with retinal organoids (RO)!

Updates: Retina

26th February, 2025

Latest Publication: Unravelling genotype-phenotype correlations in Stargardt disease using patient-derived retinal organoids

Newcells Biotech, in collaboration with Newcastle University, is proud to announce a new scientific publication showcasing cutting-edge research into Stargardt disease. In this study  patient-derived retinal…

Read update
17th October, 2024

Transforming Drug Development with 3D Retina Models

Newcells Biotech Limited, a team of internationally recognised experts in the building and application of complex models of human tissues for drug discovery, was awarded £1m to deliver their…

Read update
Newcells Biotech
11th June, 2024

Newcells Biotech strengthens executive and US team with key appointments

Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced…

Read update
5th May, 2023

ARVO Highlights

About the conference: ARVO The ARVO conference took place in the New Orleans Ernest N. Morial Convention Center.  With over 10 000 attendees, the venue was absolutely huge. If you…

Read update
iPSC-derived retinal pigment epithelial (RPE) cells
28th April, 2023

Latest innovation in retina models brings a fully characterised Retina Pigment Epithelium (RPE)

Why develop an RPE model? Retinal pigment epithelium (RPE) cells play a vital role in the retina by forming the outer blood-retinal barrier and maintaining photoreceptor and visual…

Read update
ADC, Antibody drug conjugate,
20th April, 2023

Antibody drug conjugates (ADCs) – the role of in vitro models in safety assessment

One the fastest growing approaches to treat cancer is the use of antibody drug conjugates (ADCs). Since the approval of the first antibody drug conjugate  in 2000,…

Read update
20th September, 2024

Ask an expert: What are the latest trends in in vitro models?

What are the latest trends for new in vitro models? In the field, we have been talking about very complex models, so-called organs on chip,…

Read update
9th September, 2024

Newcells Biotech launches Lung Ciliary Beat Frequency assay to enhance safety and efficacy profiling in preclinical drug development

Newcastle, UK, 09 September 2024: Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction…

Read update
28th August, 2024

Latest advances in In Vitro models

What are the latest trends for new in vitro models ? I think the latest trend that we are seeing is in terms of the ability of…

Read update
1st August, 2024

Press Release: Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…

Read update
Rhys and collin at JSOT 2024
12th July, 2024

The Intensity of Innovation: Insights from the Japanese Society of Toxicology Conference

A Unique Exhibition-Poster Integration One striking feature of JSOT is how they seamlessly integrate exhibitions with poster sessions. Exhibitors and poster presenters are…

Read update
8th July, 2024

Press Release: Newcells Biotech appoints Emile Shaffu as Director of Sales

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…

Read update

Get our latest updates straight to your inbox

Book a Call